Cash, cash equivalents and short-term investments were $18.2 million at March 31, 2024. Based on Iterum’s current operating plan, Iterum expects that its current cash, cash equivalents and short-term investments will be sufficient to fund its operations into 2025, including through the expected Prescription Drug User Fee Act date early in the fourth quarter of 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITRM:
- Iterum Therapeutics Reports First Quarter 2024 Financial Results
- Iterum Therapeutics Announces CMO Transition and Consultant Role
- Iterum Therapeutics resubmits NDA to U.S. FDA for oral sulopenem
- Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem
- Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results